Swiss Daybook: Roche Sales, Baer Settlement and Sulzer Orders

Roche Holding AG (ROG), the world’s biggest maker of cancer drugs, said first-quarter sales declined 9 percent as the Swiss franc strengthened and revenue from the Avastin tumor medicine fell.

Sales dropped to 11.1 billion francs ($12.4 billion) from 12.2 billion francs a year earlier, the Basel, Switzerland-based company said today in a statement. Analysts predicted 11.3 billion francs, the average of 22 estimates compiled by Bloomberg. Roche doesn’t release quarterly earnings.

WHAT TO WATCH: *Nestle holds annual general meeting at 2:30 p.m. in Lausanne

EQUITIES: *Roche Holding AG’s first-quarter sales declined 9 percent to 11.1 billion francs as the Swiss franc strengthened and revenue from the Avastin tumor medicine fell *Julius Baer Group Ltd. (BAER) agreed with German authorities on a one-time payment of 50 million euros to end investigations against unknown employees *Sulzer AG (SUN)’s first-quarter orders rose 12 percent to 918 million francs *Sulzer proposes Musetti to board after Summers declines re-election bid; holds annual general meeting at 10 a.m. in Winterthur *Schulthess Group AG holds shareholders’ meeting at 4:30 p.m. *Kuehne + Nagel rated new ‘neutral’ at JPMorgan

ECONOMY/POLITICS: *Credit Suisse ZEW survey at 11:00 a.m. *BAK Basel holds spring forecast meeting

MARKETS: *The SMI rose 0.2 percent to close at 6.364.30 *The SPI rose 0.2 percent to close at 5,807.59 *The Stoxx Europe 600 Index rose 0.7 percent to 278.25 *The MSCI Asia-Pacific Index rose 0.2 percent at 7:23 a.m. in Zurich *Euro-franc traded at 1.2954 at 7:20 a.m. Zurich time

To contact the reporter on this story: Corinne Gretler in Zurich at Cgretler1@bloomberg.net

To contact the editor on this story: Matthias Wabl in Zurich at mwabl@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.